Click here to close now.

Welcome!

Microsoft Cloud Authors: Aleksei Gavrilenko, Elizabeth White, Liz McMillan, Pat Romanski, Jaynesh Shah

News Feed Item

TPI Reports First Quarter Fiscal Year 2013 Financial Results

CHENGDU, China, Nov. 15, 2012 /PRNewswire/ -- Tianyin Pharmaceutical Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) announced financial results for first quarter of the fiscal year 2013.

First Quarter Fiscal Year 2013 Ended September 30, 2012 Financial Highlights:

  • Revenue was $16.0 million compared with $17.5 million in 1Q12,
  • Operating income was $2.2 million, compared with $2.1 million in 1Q12,
  • Net Income was $1.5 million compared with $1.5 million in 1Q12,
  • Earnings per share of $0.05 per basic share, and $0.05 per diluted share, compared with $0.05 per basic share, or $0.05 per diluted share in 1Q12, 
  • Cash and cash equivalents totaled $37.5 million on September 30, 2012; Operating cash flow for the quarter ended September 30, 2012 was $0.5 million, compared with $3.6 million for the quarter ended September 30, 2011.   

Comparison of results for the quarters ended September 30, 2012 and 2011:




        Quarters            

Ended September 30,





2012




2011





 

(In millions)


Sales


$

16.0



$

17.5


Cost of sales


$

9.7



$

11.7


Gross profit


$

6.2



$

5.9


Total operating expenses


$

4.1



$

3.7


Provision for income taxes


$

0.6



$

2.1


Net income


$

1.5



$

1.5


Sales for the quarter ended September 30, 2012 was $16.0 million, a decrease of 8.6% as compared to $17.5 million for the quarter ended September 30, 2011. The sales decrease was predominately the result of continuous generic pricing pressure amid healthcare reform further augmented by continued restrictive government policies to prioritize the Essential Drug List (EDL) drug sales. This simultaneously reduced the sales of our higher margin generic pharmaceuticals. However, on a positive note we did observe a stabilization of the pricing trends from a year earlier while comparing the revenue for the quarter ended September 30, 2011 with the respective period in 2010.

Our top five product sales are: Gingko mihuan oral liquid (GMOL) for stroke and cardiovascular disorders: $6.3 million; Mycophenolate mofetil capsules (MM) for renal transplant: $1.8 million; Azithromycin tablets (AZI) for infection: $0.95 million; Qingre jiedu oral liquid (QR): $0.94 million and Qianlie Shule capsules (QS) for prostate conditions: $0.42 million. These products totaled $10.4 million in sales, representing 62% of the quarterly revenue. The previous two core products Apu Shuangxin Benorylate Granules (Apu) and Xuelian Chongcao (XLCC) which are not covered by EDL or National Reimbursement List (NRL), have not reached the level to be included in the top five products mainly caused by the healthcare reform regulations that favor EDL and NRL drugs. Compared with a year earlier, the total core product sales have risen significantly from the $5.6 million for the quarter ended September 30, 2011 mainly due to the significant rise of GMOL sales: a 117% growth from $2.9 million for the quarter ended September 30, 2011. The strong sale momentum in GMOL, in our opinion, is a result of the inclusion of GMOL in a number of Provincial EDL such as the provinces of Henan and Shandong and the City of Chongqing. We expect the trend to continue for the remainder of fiscal year 2013. 

Cost of Sales for the quarter ended September 30, 2012 was $9.7 million or 60.6% of sales, as compared to $11.7 million or 66.9% of sales for the quarter ended September 30, 2011. The percentage decrease in our cost of sales from the previous period was predominately attributable to a greater mix of higher margin products. While our market analysis has not yet fully affirmed a trend of continuous margin improvement we do believe that present sales data supports a flattening and slightly positive trend in our Cost of Sales. The contribution from our distribution business through Tianyin Medicine Trading (TMT) amounted to $3.9 million at 11% gross margin.

Gross Margin for the quarter ended September 30, 2012 was 39.1% as compared to 33.4% for the quarter ended September 30, 2011. As discussed above in the segment of costs of sales, our gross margin improved predominately as a result of a greater mix of higher margin products being sold during the period supported by a leveling off of negative pricing pressures in our lower margin generic portfolio. We expect that our overall gross margin in the near term, on a quarter to quarter comparison basis will likely improve from last year based upon continued improvement of our portfolio mix of higher margin products.

Operating Expenses were $4.1 million for the quarter ended September 30, 2012, as compared to $3.7 million for the quarter ended September 30, 2011. The increase in operating expenses was mainly associated with an increase in sales and marketing costs.

Net Income was $1.5 million with a net margin of 9.6% for the quarter ended September 30, 2012, as compared to net income of $1.5 million with net margin of 8.7% for the quarter ended September 30, 2011. This was predominately a direct result of improvements in our gross margins.

Diluted earnings per share for the quarter ended September 30, 2012 were $0.05 based on 29.3 million shares compared with the earnings of $0.05 per diluted share for the quarter ended September 30, 2011, based on 29.4 million shares.

Balance Sheet and Cash Flow

As of September 30, 2012, we had working capital totaling $44.2 million, including cash and cash equivalents of $37.5 million. Net cash generated in operating activities was $0.48 million for the three months ended September 30, 2012 as compared with net cash generated from operating activities as $3.6 million for the three months ended September 30, 2011. The net decrease in operating cash flow was predominately the result of; 1) an increase in the payment of trade notes payable of $3.1 million that was due this quarter, 2) a decrease of inventory of $1.4 million, and 3) an increase of advance from customer of $1.1 million. We believe that TPI is adequately funded to meet all of our working capital and capital expenditure needs for fiscal year 2013.

Business Development & Outlook

R&D for additional indications of flagship product Gingko Mihuan (GMOL)

Our flagship product Gingko Mihuan Oral Liquid (GMOL, SFDA certification number: H20013079; patent number: 20061007800225) contributes approximately 39% to our total revenue. Clinical application and information gathered from our physicians showed that in addition to our approved indication for GMOL: cardiovascular disorders, coronary heart disease and cerebral ischemic attack including strokes, off-label use of GMOL have been indicated in hepatic diseases and ophthalmological diseases. The validity of these observations is currently being investigated.

Jiangchuan Macrolide Project (JCM)

TPI has completed the 240-ton JCM facility for the R&D, manufacturing and sale of API and chemical intermediates of macrolide antibiotics. In January 2012, JCM was approved for its GMP certification designated as "CHUAN M0799," which is valid for the period of December 31, 2011 until December 31, 2015. The JCM underwent efficiency improvement and calibration for large scale production for the initial three months of operation. By July 2012, JCM has started producing macrolide API for TPI's production of Azithromycin Dispersible Tablets (SFDA No: H20074145).

Tianyin Medicine Trading Distribution Business (TMT)

TMT is established to distribute products manufactured by both TPI and other pharmaceutical companies to fuel our expanding sales network as well as to provide synergy to our existing organic product portfolio. TMT has been distributing mainly TPI's own products since its inception in 2009. Since 2010, TPI has signed and later extended distribution contracts with Jiangsu Lianshui Pharmaceutical ("Lianshui") to distribute Lianshui-branded generic injection products including cough suppressant, antibiotics, anti-inflammatory medicines and other healthcare indications. On average, TMT distribution revenue contributed approximately $3-5 million sales per quarter to our total revenue.

Pre-extraction and formulation plant development at Qionglai Facility (QLF)

In preparation for the new Good Manufacturing Practice (GMP) standards stipulated by the PRC government in early 2011, TPI initiated the process of optimizing the manufacturing facilities and production lines in compliance with the new GMP standards by 2013. Concurrently, the city of Chengdu has re-designated various industrial parks for particular industries such as automobile, biotechnologies, pharmaceuticals and chemical engineering. As a consequence, TPI's current manufacturing facility at the Longquan district, east of Chengdu, which is designated for use by the automotive industry, is scheduled to be relocated to Qionglai city, south of Chengdu, which is designated for use by the pharmaceutical industry. The Qionglai facility (QLF) is approximately 18 miles from the Company's recently completed JCM facility. The proposed relocation project also includes our TCM pre-extraction plant, which is located near the center of city of Chengdu, a rapidly expanding residential area.

The QLF is estimated to be 80 mu or approximately 13 acres. Both pre-extraction plant and the formulation plant are to be relocated. The combined QLF plant, designed and constructed according to the latest GMP standards, is expected to relieve the current capacity saturation at TPI's facilities. The re-location and construction cost is estimated at $25 million for Phase I which, when completed in the end of calendar year 2012, will expand the current capacity by 30%. For Phase II of the QLF project, an additional $10 million in capital investment may be made to double the current capacity by calendar year 2013 if demand is required.

Fiscal Year 2013 Guidance

We are assuming that continued pricing pressures in our marketplace will remain constant for the upcoming year as we expect further reforms to be undertaken in the healthcare marketplace in China. This will continue to put pressure on our revenue growth in 2013, but we believe that JCM and TMT distribution business may help us overcome these external pressures and allow us to deliver 2013 revenue growth of approximately 10% to 15%. Therefore, we reiterate our fiscal 2013 revenue projection of approximately $75 to $80 million along with a net margin of approximately 10%.

We believe the following factors will influence the future growth perspectives of our Company: 1) Market expansion and revenue growth of TPI's core product portfolio led by flagship product Gingko Mihuan Oral Liquid (GMOL) and other major products; 2) Ramp up of JCM revenue in the fiscal year 2013; 3) The gradual stabilization of generic sales following the progressive pricing restrictions caused by the ongoing healthcare reform; 4) Steady TMT distribution revenue contribution; and 5) QLF relocation and smooth transition of production capacity. 

Management will continue to evaluate the Company's business outlook and communicate any changes on a quarterly basis or as when appropriate.

Conference Call

Senior management of TPI will host its earnings conference call for the first quarter fiscal year 2013 ending September 30, 2012 to be held at 8:30 a.m. ET on Thursday, November 15, 2012.

Interested parties may access the call by dialing 1-877-941-4774 (U.S.) or 1-480-629-9760 (International).

The conference ID is 4572569. It is advisable to dial in approximately 5 minutes prior to the start of the call.

A replay will be available by calling 1-877-870-5176 (U.S.) or 1-858-384-5517

From:  11/15/2012 @ 11:30 am E.T. To:    11/29/2012 @ 11:59 pm E.T.

Replay Pin Number:  4572569

This call is being web cast by ViaVid Broadcasting and can be accessed at ViaVid's website at the following link: http://public.viavid.com/index.php?id=102266

About TPI

Headquartered at Chengdu, China, TPI is a pharmaceutical company that specializes in the development, manufacturing, marketing and sales of patented biopharmaceutical, modernized traditional Chinese medicines, branded generics and other pharmaceuticals. TPI currently manufactures a comprehensive portfolio of 58 products, 24 of which are listed in the highly selective national medicine reimbursement list, 7 are included in the essential drug list of China. TPI's pipeline targets various high incidence healthcare indications.

For more information about TPI, please visit: http://www.tianyinpharma.com.

Safe Harbor Statement

The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.

For more information, please contact:

Investors Contact: [email protected]
Web:   http://www.tianyinpharma.com
Tel: +86-28-8551-6696 (Chengdu, China)
       +86 134-36-550011 (China)

Address:
23rd Floor Unionsun Yangkuo Plaza
No. 2, Block 3, South Renmin Road
Chengdu, 610041
China

 

TIANYIN PHARMACEUTICAL CO., INC.

Consolidated Balance Sheets

















September 30,



June 30,




2012



2012


Assets


(Unaudited)





Current assets:







Cash and cash equivalents


$

37,538,365



$

35,152,295


Restricted cash



1,583,000




3,534,550


Accounts receivable, net of allowance for doubtful accounts of $113,719









   and $113,862 at September 30, 2012 and June 30, 2012, respectively



10,264,113




11,272,367


Inventory



6,432,893




5,863,013


Advance payments



-




642,075


Other current assets



475,866




436,664


Total current assets



56,294,237




56,900,964











Property and equipment, net



26,040,538




26,458,349











Intangibles, net



20,732,243




20,958,226











Total assets


$

103,067,018



$

104,317,539











Liabilities









Current liabilities:









Accounts payable and accrued expenses


$

1,487,623



$

1,586,151


Accounts payable – construction related



410,899




740,832


Short-term bank loans



6,015,400




6,023,000


Trade notes payable



1,583,000




4,675,750


Advances from customer



1,139,760




-


Income tax payable



583,307




804,595


Other taxes payable



480,104




500,782


Other current liabilities



425,931




466,982


Total current liabilities



12,126,024




14,798,092











Total liabilities



12,126,024




14,798,092











Equity









Stockholders' equity:









Common stock, $0.001 par value, 50,000,000 shares authorized,









   29,332,791 shares issued and outstanding at September 30, 2012









   and June 30, 2012



29,446




29,446


Additional paid-in capital



30,117,997




30,104,902


Treasury stock



(135,925)




(135,925)


Statutory reserve



6,120,143




6,120,143


Retained earnings



46,563,946




45,022,329


Accumulated other comprehensive income



7,988,385




8,100,526


Total stockholders' equity



90,683,992




89,241,421











Noncontrolling interest



257,002




278,026











Total equity



90,940,994




89,519,447











Total liabilities and equity


$

103,067,018



$

104,317,539


 

 

TIANYIN PHARMACEUTICAL CO., INC.

Consolidated Statements of Operations and Comprehensive Income

(Unaudited)







For the Three Months Ended




September 30,




2012



2011









Sales


$

15,971,697



$

17,528,578











Cost of sales



9,727,993




11,675,529











Gross profit



6,243,704




5,853,049











Operating expenses









Selling expenses



2,761,438




2,477,326


General and administrative expenses



1,121,533




1,019,122


Research and development



215,930




210,715


Total operating expenses



4,098,901




3,707,163











Income from operations



2,144,803




2,145,886











Other income (expenses):









Interest income



67,602




34,961


Interest expense



(108,404)




(49,845)


Other income



-




(4,718)


Total other expenses



(40,802)




(19,602)











Income before provision for income taxes



2,104,001




2,126,284











Provision for income taxes



583,048




619,067











Net income



1,520,953




1,507,217











Less: net income attributable to noncontrolling interest



(20,664)




(18,023)











Net income attributable to Tianyin Pharmaceutical Co., Inc.


$

1,541,617



$

1,525,240











Basic earnings per share


$

0.05



$

0.05


Diluted earnings per share


$

0.05



$

0.05











Weighted average number of common shares outstanding:









Basic



29,332,791




29,396,276


Diluted



29,332,791




29,396,276


 

TIANYIN PHARMACEUTICAL CO., INC.

Consolidated Statements of Comprehensive Income

(Unaudited)







For the Three Months Ended




September 30,




2012



2011









Net income


$

1,520,953



$

1,507,217











Other comprehensive income (loss)









Foreign currency translation adjustment



(112,500)




947,507











Total other comprehensive income (loss)



(112,500)




947,507











Total Comprehensive income



1,408,453




2,454,724











Less: Comprehensive income (loss) attributable to the noncontrolling interest



(21,024)




237,404











Comprehensive income attributable to









Tianyin Pharmaceutical Co., Inc.


$

1,429,477



$

2,217,320











 

TIANYIN PHARMACEUTICAL CO., INC.

Consolidated Statements of Cash Flows

(Unaudited)







For the Three Months Ended




September 30,




2012



2011


Cash flows from operating activities:







Net Income


$

1,520,953



$

1,507,217


Adjustments to reconcile net income to net cash









provided by (used in) operating activities:









Depreciation and amortization



583,704




286,668


Share-based payments



13,095






Provision for bad debts



-




43,558


Changes in current assets and current liabilities:









Accounts receivable



993,591




699,626


Inventory



(577,022)




820,036


Advance payments



640,981




581,122


Other current assets



(39,736)




(63,523)


Accounts payable and accrued expenses



(96,477)




828,517


Accounts payable – construction related



(328,853)




(238,357)


Trade notes payable



(3,085,485)




-


Advances from customer



1,139,256




-


Income tax payable



(220,175)




(368,238)


Other taxes payable



(20,037)




(342,478)


Other current liabilities



(40,444)




(129,363)


Total adjustments



(1,037,602)




2,117,568











Net cash provided by operating activities



483,351




3,624,785











Cash flows from investing activities:









Addition to property and equipment



-




(113,819)


Additions to intangible assets – approved drugs



-




(765,282)


Additions to intangible assets – land use right



-




(1,815,804)











Net cash used in investing activities



-




(2,694,905)











Cash flows from financing activities:









Restricted cash



1,946,229




(1,530,564)


Proceeds from short-term bank loans



-




1,561,800











Net cash provided by financing activities



1,946,229




31,236











Effect of foreign currency translation on cash



(43,510)




621,270











Net increase in cash and cash equivalents



2,386,070




1,582,386











Cash and cash equivalents – beginning



35,152,295




31,724,906











Cash and cash equivalents – ending


$

37,538,365



$

33,307,292











Supplemental disclosures of cash activities









Cash paid for interest


$

108,404



$

49,845


Cash paid for income taxes


$

803,579



$

987,304


 

 

SOURCE Tianyin Pharmaceutical Co., Inc.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

@ThingsExpo Stories
SYS-CON Events announced today that Intelligent Systems Services will exhibit at the 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. Established in 1994, Intelligent Systems Services Inc. is located near Washington, DC, with representatives and partners nationwide. ISS’s well-established track record is based on the continuous pursuit of excellence in designing, implementing and supporting nationwide clients’ mission-critical systems. ISS has completed many successful projects in Healthcare, Commercial, Manu...
The Internet of Things is not only adding billions of sensors and billions of terabytes to the Internet. It is also forcing a fundamental change in the way we envision Information Technology. For the first time, more data is being created by devices at the edge of the Internet rather than from centralized systems. What does this mean for today's IT professional? In this Power Panel at @ThingsExpo, moderated by Conference Chair Roger Strukhoff, panelists addressed this very serious issue of profound change in the industry.
With major technology companies and startups seriously embracing IoT strategies, now is the perfect time to attend @ThingsExpo in Silicon Valley. Learn what is going on, contribute to the discussions, and ensure that your enterprise is as "IoT-Ready" as it can be! Internet of @ThingsExpo, taking place Nov 3-5, 2015, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 17th Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The Internet of Things (IoT) is the most profound change in personal an...
SYS-CON Events announced today that WHOA.com, an ISO 27001 Certified secure cloud computing company, participated as “Bronze Sponsor” of SYS-CON's 16th International Cloud Expo® New York, which took place June 9-11, 2015, at the Javits Center in New York City, NY. WHOA.com is a leader in next-generation, ISO 27001 Certified secure cloud solutions. WHOA.com offers a comprehensive portfolio of best-in-class cloud services for business including Infrastructure as a Service (IaaS), Secure Cloud Desktop, Cloud Storage, Disaster Recovery, Integrated Applications and Security.
SYS-CON Events announced today that kintone has been named “Bronze Sponsor” of SYS-CON's 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. kintone promotes cloud-based workgroup productivity, transparency and profitability with a seamless collaboration space, build your own business application (BYOA) platform, and workflow automation system.
Discussions about cloud computing are evolving into discussions about enterprise IT in general. As enterprises increasingly migrate toward their own unique clouds, new issues such as the use of containers and microservices emerge to keep things interesting. In this Power Panel at 16th Cloud Expo, moderated by Conference Chair Roger Strukhoff, panelists addressed the state of cloud computing today, and what enterprise IT professionals need to know about how the latest topics and trends affect their organization.
SYS-CON Events announced today that SoftLayer, an IBM company, has been named “Gold Sponsor” of SYS-CON's 17th International Cloud Expo®, which will take place November 3–5, 2015 at the Santa Clara Convention Center in Santa Clara, CA. SoftLayer operates a global cloud infrastructure platform built for Internet scale. With a global footprint of data centers and network points of presence, SoftLayer provides infrastructure as a service to leading-edge customers ranging from Web startups to global enterprises. SoftLayer’s modular architecture, full-featured API, and sophisticated automation pro...
The enterprise market will drive IoT device adoption over the next five years. In his session at @ThingsExpo, John Greenough, an analyst at BI Intelligence, division of Business Insider, analyzed how companies will adopt IoT products and the associated cost of adopting those products. John Greenough is the lead analyst covering the Internet of Things for BI Intelligence- Business Insider’s paid research service. Numerous IoT companies have cited his analysis of the IoT. Prior to joining BI Intelligence, he worked analyzing bank technology for Corporate Insight and The Clearing House Payment...
17th Cloud Expo, taking place Nov 3-5, 2015, at the Santa Clara Convention Center in Santa Clara, CA, will feature technical sessions from a rock star conference faculty and the leading industry players in the world. Cloud computing is now being embraced by a majority of enterprises of all sizes. Yesterday's debate about public vs. private has transformed into the reality of hybrid cloud: a recent survey shows that 74% of enterprises have a hybrid cloud strategy. Meanwhile, 94% of enterprises are using some form of XaaS – software, platform, and infrastructure as a service.
SYS-CON Events announced today that CommVault has been named “Bronze Sponsor” of SYS-CON's 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. A singular vision – a belief in a better way to address current and future data management needs – guides CommVault in the development of Singular Information Management® solutions for high-performance data protection, universal availability and simplified management of data on complex storage networks. CommVault's exclusive single-platform architecture gives companies unp...
"ciqada is a combined platform of hardware modules and server products that lets people take their existing devices or new devices and lets them be accessible over the Internet for their users," noted Geoff Engelstein of ciqada, a division of Mars International, in this SYS-CON.tv interview at @ThingsExpo, held June 9-11, 2015, at the Javits Center in New York City.
Buzzword alert: Microservices and IoT at a DevOps conference? What could possibly go wrong? In this Power Panel at DevOps Summit, moderated by Jason Bloomberg, the leading expert on architecting agility for the enterprise and president of Intellyx, panelists peeled away the buzz and discuss the important architectural principles behind implementing IoT solutions for the enterprise. As remote IoT devices and sensors become increasingly intelligent, they become part of our distributed cloud environment, and we must architect and code accordingly. At the very least, you'll have no problem fillin...
The 17th International Cloud Expo has announced that its Call for Papers is open. 17th International Cloud Expo, to be held November 3-5, 2015, at the Santa Clara Convention Center in Santa Clara, CA, brings together Cloud Computing, APM, APIs, Microservices, Security, Big Data, Internet of Things, DevOps and WebRTC to one location. With cloud computing driving a higher percentage of enterprise IT budgets every year, it becomes increasingly important to plant your flag in this fast-expanding business opportunity. Submit your speaking proposal today!
The 5th International DevOps Summit, co-located with 17th International Cloud Expo – being held November 3-5, 2015, at the Santa Clara Convention Center in Santa Clara, CA – announces that its Call for Papers is open. Born out of proven success in agile development, cloud computing, and process automation, DevOps is a macro trend you cannot afford to miss. From showcase success stories from early adopters and web-scale businesses, DevOps is expanding to organizations of all sizes, including the world's largest enterprises – and delivering real results. Among the proven benefits, DevOps is corr...
Internet of Things (IoT) will be a hybrid ecosystem of diverse devices and sensors collaborating with operational and enterprise systems to create the next big application. In their session at @ThingsExpo, Bramh Gupta, founder and CEO of robomq.io, and Fred Yatzeck, principal architect leading product development at robomq.io, discussed how choosing the right middleware and integration strategy from the get-go will enable IoT solution developers to adapt and grow with the industry, while at the same time reduce Time to Market (TTM) by using plug and play capabilities offered by a robust IoT ...
SYS-CON Events announced today that Secure Infrastructure & Services will exhibit at SYS-CON's 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. Secure Infrastructure & Services (SIAS) is a managed services provider of cloud computing solutions for the IBM Power Systems market. The company helps mid-market firms built on IBM hardware platforms to deploy new levels of reliable and cost-effective computing and high availability solutions, leveraging the cloud and the benefits of Infrastructure-as-a-Service (IaaS...
Today air travel is a minefield of delays, hassles and customer disappointment. Airlines struggle to revitalize the experience. GE and M2Mi will demonstrate practical examples of how IoT solutions are helping airlines bring back personalization, reduce trip time and improve reliability. In their session at @ThingsExpo, Shyam Varan Nath, Principal Architect with GE, and Dr. Sarah Cooper, M2Mi’s VP Business Development and Engineering, will explore the IoT cloud-based platform technologies driving this change including privacy controls, data transparency and integration of real time context wi...
The basic integration architecture, as defined by ESBs, hasn’t changed for more than a decade. Most cloud integration providers still rely on an ESB architecture and their proprietary connectors. As a result, enterprise integration projects suffer from constraints of availability and reliability of these connectors that are not re-usable across other integration vendors. However, the rapid adoption of APIs and almost ubiquitous availability of APIs amongst most SaaS and Cloud applications are rapidly redefining traditional integration approaches and their reliance on proprietary connectors. ...
SYS-CON Events announced today that Dyn, the worldwide leader in Internet Performance, will exhibit at SYS-CON's 17th International Cloud Expo®, which will take place on November 3-5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. Dyn is a cloud-based Internet Performance company. Dyn helps companies monitor, control, and optimize online infrastructure for an exceptional end-user experience. Through a world-class network and unrivaled, objective intelligence into Internet conditions, Dyn ensures traffic gets delivered faster, safer, and more reliably than ever.
Explosive growth in connected devices. Enormous amounts of data for collection and analysis. Critical use of data for split-second decision making and actionable information. All three are factors in making the Internet of Things a reality. Yet, any one factor would have an IT organization pondering its infrastructure strategy. How should your organization enhance its IT framework to enable an Internet of Things implementation? In his session at @ThingsExpo, James Kirkland, Red Hat's Chief Architect for the Internet of Things and Intelligent Systems, described how to revolutionize your archit...